Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma

Trial Profile

Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Choroid neoplasms; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Cohort 2
  • Most Recent Events

    • 08 Aug 2011 Planned end date changed from Aug 2011 to Aug 2012 as reported by ClinicalTrials.gov.
    • 08 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top